ライフサイエンスコーパス: fecal microbiota

1 r humanized (ex-GF mice colonized with human fecal microbiota).

2 ffects of co-habitation on skin than oral or fecal microbiota.

3 ative PCR to monitor and quantify changes in fecal microbiota.

4 ing clinical challenge mostly originating in fecal microbiota.

5 agents that relatively spare the indigenous fecal microbiota.

6 protocol for 16S ribosomal RNA sequencing of fecal microbiota.

7 Fecal microbiota 16S rRNA genes, immune cell distributio

8 ced overlap with the deeply sequenced twins' fecal microbiota (18.3 +/- 0.3%, 15.3 +/- 0.3%).

9 assic approaches, we found no differences in fecal microbiota abundance or composition between patien

10 Fecal microbiota analyses were performed on patients' st

11 Fecal microbiota analysis of 3 successful FT recipients

12 levels of tryptophan and composition of the fecal microbiota, analyzed by 16S ribosomal DNA amplicon

13 Here, we explore links between the fecal microbiota and abdominal adiposity using body comp

14 amily member 3 alpha gene (REG3A) alters the fecal microbiota and affects development of colitis in m

15 association between low diversity childhood fecal microbiota and increased diabetes risk.

16 te temporal changes in the concentrations of fecal microbiota and short-chain fatty acids (SCFAs) in

17 dietary protein increased the density of the fecal microbiota and the severity of colitis in SPF mice

18 The composition of the fecal microbiota associated with serum levels of tryptop

19 crolimus, and mycophenolate mofetil modified fecal microbiota at the family level in each experimenta

20 n was associated with the composition of the fecal microbiota, but not with constipation or colonic t

21 Metagenomic phylogenetic analysis of fecal microbiota by deep sequencing revealed considerabl

22 We profiled the fecal microbiota by pyrosequencing the gene encoding 16S

23 iltrates from donor stool (FFT), rather than fecal microbiota, can be sufficient to restore normal st

24 results in reduced IL-18 levels and altered fecal microbiota characterized by expanded representatio

25 Prednisolone disrupted fecal microbiota community structure, decreased Bacteroi

26 oos and hosted a strikingly low diversity of fecal microbiota compared to individuals born in natural

27 Fecal microbiota composition analysis was performed in a

28 In the subcohort of 42 children with fecal microbiota composition analysis, the children with

29 lock component, abolished rhythmicity in the fecal microbiota composition in both genders.

30 s of metabolic disease and inflammation, and fecal microbiota composition were assessed.

31 .Fecal and serum menaquinone concentrations, fecal microbiota composition, and plasma and fecal cytok

32 eral and adipose tissue insulin sensitivity, fecal microbiota composition, plasma and fecal SCFA, ene

33 , lifetime antibiotic use after weaning, and fecal microbiota composition.

34 ndry and metagenomics to show that the human fecal microbiota consists largely of taxa and predicted

35 from healthy donors or were given autologous fecal microbiota (control); each transplant was administ

36 ently, here we demonstrate that the phyla of fecal microbiota differ substantially between L1-KO mice

37 In this setting, fecal microbiota, evaluated by 16S rRNA gene amplicon se

38 here has been growing interest in the use of fecal microbiota for the treatment of patients with chro

39 We transplanted fecal microbiota from adult female twin pairs discordant

40 T hosts that were recolonized with dysbiotic fecal microbiota from Nod2-deficient mice.

41 ecal microbiota from the mice which received fecal microbiota from patients with constipation also up

42 In this study, fecal microbiota from patients with constipation and hea

43 The mice which received fecal microbiota from patients with constipation present

44 Fecal microbiota from REG3A-TG mice protect non-TG mice

45 Moverover, fecal microbiota from the mice which received fecal micr

46 We characterized the fecal microbiota from these two species by pyrosequencin

47 from different studies of the Western adult fecal microbiota generally clustered by study, and the 1

48 Variation in the human fecal microbiota has previously been associated with bod

49 015), and gamma-proteobacteria domination of fecal microbiota (HR, 2.64; 95% CI, 1.10-5.65; P = 0.031

50 Assessment of fecal microbiota identifies patients at highest risk for

51 This study compared the structure of the fecal microbiota in 29 mestizo children aged 7-18 years,

52 provide novel insights into the role of the fecal microbiota in cardio-metabolic disease with clear

53 circadian rhythmicity and composition of the fecal microbiota in mice.

54 We compared the colonic mucosal and fecal microbiota in patients with chronic constipation a

55 to determine its effects on symptoms and the fecal microbiota in patients with IBS.

56 ubstituting antibiotics, this study assessed fecal microbiota in pigs from different dietary treatmen

57 icrobiota are altered in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 3

58 one prebiotic formula on the same inoculated fecal microbiota in two frequently used batch systems: p

59 ntries, which correlates with alterations in fecal microbiota (microflora) and widespread use of anti

60 spread use of antibiotics and alterations in fecal microbiota ("microflora").

61 emerging under ciprofloxacin pressure in the fecal microbiota, no proof of selection of quinolone-res

62 Therapeutic transplantation of fecal microbiota normalizes brain lesion-induced dysbios

63 A similar shift in the composition of the fecal microbiota occurred after a few months in TG mice

64 iple antimicrobial resistance genes), in the fecal microbiota of 147 mothers and their children sampl

65 The fecal microbiota of 2-month-old infants was considerably

66 acterize bacterial strain composition in the fecal microbiota of 37 U.S. adults sampled for up to 5 y

67 rtium of bacterial strains cultured from the fecal microbiota of a 6-month-old stunted Malawian infan

68 nce during the first 3 wk of life within the fecal microbiota of an infant born at 28-wk gestation.

69 irus-like particles (VLPs) purified from the fecal microbiota of five healthy humans.

70 The fecal microbiota of Fut2(-) mice that lack fucosylated h

71 in (150 mg 4 times daily for 10 days) on the fecal microbiota of healthy humans for a period of 1 yea

72 al 16S ribosomal RNA gene sequences from the fecal microbiota of humans and 59 other mammalian specie

73 The fecal microbiota of mice that express hREG3A had a signi

74 Here we analyzed circadian rhythms in the fecal microbiota of mice using deep sequencing, and foun

75 Characterization of the fecal microbiota of patients undergoing allogeneic hemat

76 We profiled the fecal microbiota of patients with CDAD (both initial and

77 lic consequences and specific effects on the fecal microbiota of protein and zinc deficiency were pro

78 The fecal microbiota of the hospitalized subjects had abnorm

79 The fecal microbiota of vaginally delivered infants (both ne

80 However, the profiles of fecal microbiota only partially replicate those of the m

81 Although no significant changes in fecal microbiota or SCFAs were observed during enteral f

82 Fecal microbiota profiles from overweight (n = 29) and o

83 The groups had similar fecal microbiota profiles, serum markers of inflammation

84 significantly disturbed composition whereas fecal microbiota recovered a similar composition to cont

85 on deficiency altered the composition of the fecal microbiota, reduced mucosal barrier function, and

86 roach begins by identifying uncultured human fecal microbiota samples that transmit immune phenotypes

87 Sigmoid colonic mucosal and fecal microbiota samples were collected from 25 healthy

88 Fecal microbiota showed covariation with mucosal adheren

89 Two fecal microbiota signatures (Clostridium and Klebsiella

90 SIRT1 iKO mice also had altered fecal microbiota starting at 4-6 months of age compared

91 NA-based analysis of the T-bet(-/-)Rag2(-/-) fecal microbiota suggest that the structure of the endog

92 systematic compositional differences in the fecal microbiota that occurred with age and between West

93 cal microbiome and were partially rescued by fecal microbiota transfer.

94 We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI usin

95 pose of this article is to review the use of fecal microbiota transplant (FMT) in the treatment of pe

96 Fecal microbiota transplant (FMT) is a highly efficaciou

97 metronidazole, vancomycin, fidaxomicin, and fecal microbiota transplant (FMT).

98 ulate various microbial communities, such as fecal microbiota transplant and bioreactor systems' opti

99 While fecal microbiota transplant has gained increasing popula

100 We intend to review the most recent data on fecal microbiota transplantation (FMT) and critically di

101 cal evaluation of the safety and efficacy of fecal microbiota transplantation (FMT) as a potential th

102 In particular, fecal microbiota transplantation (FMT) as a treatment st

103 current Clostridium difficile infection with fecal microbiota transplantation (FMT) at a tertiary ref

104 Fecal microbiota transplantation (FMT) could be a novel

105 We hypothesized that fecal microbiota transplantation (FMT) could be used to

106 The role of fecal microbiota transplantation (FMT) for Clostridium d

107 se recovery is apparent given the success of fecal microbiota transplantation (FMT) for recurrent CDI

108 ral case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative co

109 Fecal microbiota transplantation (FMT) from cancer patie

110 Fecal microbiota transplantation (FMT) has been demonstr

111 Fecal microbiota transplantation (FMT) has been shown to

112 Fecal microbiota transplantation (FMT) has been shown to

113 round: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clos

114 BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is a highly effec

115 Fecal microbiota transplantation (FMT) is a highly effec

116 Fecal microbiota transplantation (FMT) is a highly effec

117 Fecal microbiota transplantation (FMT) is a promising, b

118 Fecal microbiota transplantation (FMT) is an alternative

119 Fecal microbiota transplantation (FMT) may improve dysbi

120 While fecal microbiota transplantation (FMT) presents an attra

121 PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a

122 We report a case in which fecal microbiota transplantation (FMT) utilized for rela

123 rs of antibiotic-resistant microbes and that fecal microbiota transplantation (FMT) would reduce the

124 Fecal microbiota transplantation (FMT), a safe, effectiv

125 of the organism has led to increased use of fecal microbiota transplantation (FMT).

126 n, 15.4% vs vancomycin, 25.3%; P = .005) and fecal microbiota transplantation (response rates of 83%-

127 most current and best methods for performing fecal microbiota transplantation and summarize clinical

128 a diverse intestinal microbial population by fecal microbiota transplantation attenuates disease and

129 developed and higher quality data to support fecal microbiota transplantation for treating recurrent

130 udy reported higher than 80% success rate of fecal microbiota transplantation for treatment of recurr

131 Fecal microbiota transplantation is an efficacious and i

132 Fecal microbiota transplantation is another emerging the

133 Fecal microbiota transplantation is associated with symp

134 Fecal microbiota transplantation is increasingly used to

135 Fecal microbiota transplantation led to resolution of re

136 Fecal microbiota transplantation may have a substantial

137 Third, we report our use of fecal microbiota transplantation to face severe Clostrid

138 Intervention: Fecal microbiota transplantation with donor stool (heter

139 Fecal microbiota transplantation, performed in one patie

140 After fecal microbiota transplantation, the SERT expression in

141 Fecal microbiota transplantation, where healthy donor st

142 ridium difficile infection as effectively as fecal microbiota transplantation.

143 or example, administration of probiotics and fecal microbiota transplantation.

144 commended laboratory screening practices for fecal microbiota transplantation.

145 nd could be transferred to germ-free mice by fecal microbiota transplantation.

146 We also discuss case reports of fecal microbiota transplantations for different disorder

147 We assessed brain activation patterns, fecal microbiota, urine metabolome profiles, serum marke

148 ygen species (ROS) in bacterial cultures and fecal microbiota using 2',7'-dichlorofluorescein diaceta

149 Fecal microbiota varied with diet; the concentration of

150 The profile of the fecal microbiota was associated with colonic transit and

151 The profile of the fecal microbiota was associated with colonic transit bef

152 Diversity and composition of fecal microbiota were determined by 16S ribosomal RNA ge

153 fects of interventions and breast-feeding on fecal microbiota were investigated.

154 Taxonomic profiles of fecal microbiota were obtained prospectively, and conven

155 after each of the treatments, and changes in fecal microbiota were quantified.

156 w that the abundances of Escherichia coli in fecal microbiota were significantly higher in young chil

157 lthy donors and those who received their own fecal microbiota, which may be due to limited numbers.